Wuhan General Gr Chn
Wuhan General Group (China), Inc., a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Reno, Nevada.
Wuhan General Gr Chn (WUHN) - Net Assets
Latest net assets as of September 2022: $-6.97 Million USD
Based on the latest financial reports, Wuhan General Gr Chn (WUHN) has net assets worth $-6.97 Million USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($191.36K) and total liabilities ($7.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.97 Million |
| % of Total Assets | -3644.9% |
| Annual Growth Rate | -20.76% |
| 5-Year Change | -99.51% |
| 10-Year Change | N/A |
| Growth Volatility | 77.3 |
Wuhan General Gr Chn - Net Assets Trend (2006–2021)
This chart illustrates how Wuhan General Gr Chn's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wuhan General Gr Chn (2006–2021)
The table below shows the annual net assets of Wuhan General Gr Chn from 2006 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $577.37K | +13.91% |
| 2020-12-31 | $506.86K | +188.10% |
| 2019-12-31 | $-575.33K | -100.54% |
| 2012-12-31 | $107.33 Million | -8.71% |
| 2011-12-31 | $117.58 Million | +4.68% |
| 2010-12-31 | $112.32 Million | +9.41% |
| 2009-12-31 | $102.66 Million | +9.70% |
| 2008-12-31 | $93.59 Million | +69.05% |
| 2007-12-31 | $55.36 Million | +192.24% |
| 2006-12-31 | $18.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan General Gr Chn's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 128.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.49K | 0.95% |
| Other Comprehensive Income | $603.00 | 0.10% |
| Other Components | $2.47 Million | 427.91% |
| Total Equity | $577.37K | 100.00% |
Wuhan General Gr Chn Competitors by Market Cap
The table below lists competitors of Wuhan General Gr Chn ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
199290
KO:199290
|
$2.36K |
|
International Steels Ltd
KAR:ISL
|
$2.36K |
|
NXNT
OTCQB:NXNT
|
$2.37K |
|
Checkit PLC
LSE:CKT
|
$2.37K |
|
Thanh Thai Group JSC
VN:KKC
|
$2.36K |
|
Novonix Limited
BE:GC3
|
$2.36K |
|
Develop North PLC
LSE:DVNO
|
$2.36K |
|
DOLPHIN CAP INVEST
BE:D5S
|
$2.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan General Gr Chn's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 506,860 to 577,368, a change of 70,508 (13.9%).
- Net loss of 1,713,443 reduced equity.
- Other comprehensive income decreased equity by 690,635.
- Other factors increased equity by 2,474,586.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.71 Million | -296.77% |
| Other Comprehensive Income | $-690.63K | -119.62% |
| Other Changes | $2.47 Million | +428.6% |
| Total Change | $- | 13.91% |
Book Value vs Market Value Analysis
This analysis compares Wuhan General Gr Chn's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.01 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan General Gr Chn utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -296.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12086.93%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.32x
- Recent ROE (-296.77%) is below the historical average (-15.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 16.90% | 19.17% | 0.33x | 2.66x | $1.31 Million |
| 2007 | 26.86% | 18.02% | 0.82x | 1.81x | $9.33 Million |
| 2008 | 17.25% | 13.61% | 0.77x | 1.66x | $6.79 Million |
| 2009 | 12.88% | 9.16% | 0.53x | 2.65x | $1.89 Million |
| 2010 | 4.09% | 2.91% | 0.45x | 3.10x | $-4.63 Million |
| 2011 | -4.47% | -3.03% | 0.47x | 3.16x | $-12.49 Million |
| 2012 | -13.92% | -13.18% | 0.28x | 3.77x | $-18.20 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-152.86K |
| 2020 | 80.89% | 1232.11% | 0.06x | 1.18x | $359.31K |
| 2021 | -296.77% | -12086.93% | 0.02x | 1.32x | $-1.77 Million |
Industry Comparison
This section compares Wuhan General Gr Chn's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan General Gr Chn (WUHN) | $-6.97 Million | 16.90% | N/A | $2.36K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |